Key result
Carvedilol reduces hepatic steatosis in preclinical MAFLD models via APOC3 downregulation and AMPK activation.
Why the study?
Carvedilol may have metabolic regulatory properties in hepatic lipid metabolism, and APOC3 is implicated in hepatic steatosis. The effects of carvedilol on hepatic lipid synthesis and the potential role of APOC3 downregulation in metabolic-associated fatty liver disease required investigation.
Does carvedilol reduce hepatic lipid accumulation and improve metabolic-associated fatty liver disease in in vivo and in vitro models?
Does carvedilol reduce hepatic lipid accumulation and improve metabolic-associated fatty liver disease in in vivo and in vitro models?
Preclinical findings demonstrate that carvedilol reduces hepatic lipid accumulation and liver injury by downregulating APOC3 and activating AMPK signaling, suggesting a potential therapeutic role in metabolic-associated fatty liver disease.
Answers are grounded in this paper and cite their sources.
Carvedilol may aid hepatic lipid metabolism in MAFLD with CV disease; leaves open effects on clinical outcomes pending randomized trials.
Background/Objectives: Metabolic-associated fatty liver disease (MAFLD) has emerged as a significant global health concern, closely linked to metabolic syndrome and characterized by hepatic fat accumulation in the absence of excessive alcohol consumption. Carvedilol (CARV), a non-selective β-blocker, has long been used in the treatment of cardiovascular conditions, but emerging evidence suggests that it also exhibits metabolic regulatory properties, particularly in hepatic lipid metabolism. Apolipoprotein C3 (APOC3) is a key regulator of triglyceride metabolism and has been implicated in the development of hepatic steatosis. This research aimed to investigate the effects of carvedilol on hepatic lipid synthesis and the potential role of APOC3 downregulation in this process. Methods: Through a combination of in vivo and in vitro models. Results:we demonstrate that CARV significantly reduces hepatic lipid accumulation by downregulating APOC3 expression. Mechanistic assays revealed that CARV suppresses de novo lipogenesis and facilitates fatty acid β-oxidation by activating the AMPK signaling pathway in hepatocytes. In HFF-induced MAFLD mice, CARV ameliorated hepatic steatosis, liver injury, lobular inflammation and collagen deposition. Conclusions: Collectively, our findings identify a novel metabolic protective function of carvedilol, providing a potential therapeutic strategy for MAFLD and related metabolic diseases.
No takes yet. Share an insight, caveat, or question.
Luan et al. (2026) studied Metabolic-associated fatty liver disease (MAFLD). Carvedilol (CARV) was evaluated on Hepatic lipid accumulation and APOC3 expression. Carvedilol significantly reduced hepatic lipid accumulation and ameliorated steatosis in preclinical MAFLD models by downregulating APOC3 and activating AMPK signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: